AI-powered nodule detection, reporting, and patient management for enhanced
efficiency and accuracy in lung cancer diagnosis
DeepHealth Lung is an AI-powered solution designed to enhance
lung cancer
diagnosis and reporting. It integrates seamlessly into existing Picture Archiving and
Communication Systems (PACS), offering both onsite and cloud deployment options to minimize
workflow disruptions. Trained on over 40,000 scans, DeepHealth Lung automates the detection,
classification, quantification, and growth assessment of pulmonary nodules, identifying
solid
and sub-solid nodules ranging from 3 to 30mm with 95% sensitivity and no more than two false
positives per scan.
The system provides accurate measurements of nodule diameters
and volumes, and can automatically retrieve prior scans to calculate growth percentage and
volume doubling time. Widely adopted across nearly 100 locations in the UK and EU, including
41 out
of 45 sites in the UK’s Targeted Lung Health Checks program, DeepHealth Lung processes over
50,000 scans monthly, delivering standardized, customizable, and shareable lung nodule
reports to support
efficient clinical workflows.
“I have reduced my chest CT reporting time by
about 50%. The volumetry is also fantastic; it saves me from manually performing the
analysis. Ultimately, a much more robust nodule follow-up –in half the time.”
Dr. Katharine Johnson
Consultant Radiologist at Salisbury NHS (UK)
“I love the detection indications. It’s a simple
yet effective solution that really helps me to report nodules faster. I know exactly where
to find them.”
Dr. Caroline McCann
Responsible Radiologist, Liverpool Heart and Chest Hospital (UK)
Please accept
statistics and marketing
cookies to watch this video. Change consent
Beyond The Diagnosis: Transforming Cancer Care Through
Innovation
Find out how those who live with and work with cancer are rewriting the
narrative in this digital series presented by Union for International Cancer Control and
produced for them by BBC StoryWorks Commercial Productions.
The series explores innovative solutions for cancer prevention, diagnosis,
treatment and care, and spotlights DeepHealth’s role in transforming lung cancer screening.
RadNet, Inc. (NASDAQ: RDNT) reported record quarterly revenue and Adjusted EBITDA on August 7, 2024, and revised upwards its 2024 financial guidance ranges. DeepHealth, a wholly-owned subsidiary of RadNet, contributes to the parent company’s financial performance as the Digital Health segment.
Visit DeepHealth at Stand 8 during the BSTI Annual Meeting to explore our AI-powered thoracic imaging solutions. Our team will demonstrate how our advanced algorithms enhance detection accuracy and streamline radiologist workflows for chest CT and X-ray interpretation. Experience firsthand how our technology can reduce reading time while improving diagnostic confidence.
Los Angeles, CA – June 4, 2025, RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidiary DeepHealth, announced today that it has completed the acquisition of See-Mode Technologies PTE LTD (“See-Mode”), a global innovator in AI for ultrasound imaging.
Disclaimers:
DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc., and
DeepHeath Lung Tracker is manufactured as Veye Clinic by Aidence BV for DeepHealth Inc.
Not all products and functionalities are commercially available in all countries. For clearance and commercial
availability in your geography of functionalities listed and compatibility with other systems, please contact us.